Sa1681 Long Term Treatment Outcome of Patients With Gastric Vascular Ectasia Treated With Argon Plasma Coagulation

Sa1681 Long Term Treatment Outcome of Patients With Gastric Vascular Ectasia Treated With Argon Plasma Coagulation

Abstracts Sa1681 Long Term Treatment Outcome of Patients With Gastric Vascular Ectasia Treated With Argon Plasma Coagulation Doron Boltin*, Rachel Gi...

46KB Sizes 0 Downloads 39 Views

Abstracts

Sa1681 Long Term Treatment Outcome of Patients With Gastric Vascular Ectasia Treated With Argon Plasma Coagulation Doron Boltin*, Rachel Gingold-Belfer, Lev Lichtenstein, Yaron Niv Rabin Medical Center, Petah Tikva, Israel Background: gastric vascular ectasia is an uncommon cause of upper gastrointestinal (UGI) bleeding. Long term data regarding the efficacy of argon plasma coagulation (APC) for the treatment of gastric vascular ectasia are lacking. Methods: we retrospectively identified consecutive patients between January 2005 and December 2010, treated with APC for an index diagnosis of gastric vascular ectasia. Clinical and endoscopic features and APC treatment success were recorded. Treatment success was determined by resolution of symptoms and stabilization of hemoglobin level at 30% above baseline. Results: 62 patients (28 (45.2%) males) aged 72.612.8 years, were identified, including 159 upper endoscopies (mean 2.6, range 1-10) and 140 APC sessions (mean 2.3, range 1-10). Duration of follow-up was 46.926.5 months. Treatment success was achieved in 16 (25.8%) patients. Predictors of success included older age, focal pattern, lack of co-morbid liver failure or collagen vascular disease, use of antiplatelet or anticoagulant drugs and lower baseline hemoglobin. 26 (41.9%) patients died during follow-up. Conclusion: APC is safe and effective for the initial management of gastric vascular ectasia, however most patients do not experience long term resolution of UGI bleeding and anemia.

Predictors of treatment success Variable

p

Older age Absence of predisposing comorbidityx Number of APC treatments focal ectasia Antiplatelet or antiaggregant Low baseline Hb

0.038 0.019 0.005 0.02 0.02 0.004

xAbsence of liver disease, collagen vascular disease, hereditary hemorrhagic telangiectasia or gastric irradiation

Kaplan-meier survival for primary outcomes a, APC-free survival; b, overall survival.

AB300 GASTROINTESTINAL ENDOSCOPY Volume 79, No. 5S : 2014

www.giejournal.org